Article info
PDFMultiple sclerosis
Research paper
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
- Correspondence to Dr Francesco Patti, Department “G.F.Ingrassia”, Multiple Sclerosis Center, University of Catania, Teaching Hospital Policlinico “G.Rodolico”, Via S. Sofia 78, Catania 95123, Italy; patti{at}unict.it
Citation
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
Publication history
- Received October 28, 2015
- Revised February 29, 2016
- Accepted March 5, 2016
- First published May 9, 2016.
Online issue publication
August 12, 2016
Article Versions
- Previous version (12 August 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/